Aurada Cholapranee, MD
Gastroenterology · Boston, MANPI 1427463132
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $461 of the $541 with a category attached, or 85.2%. 6 manufacturers reported payments, led by Ironwood Pharmaceuticals, Inc at 23.1% of the total. Reporting peaked in 2021 at $287 and has fallen 85.7% since, to $41 in 2023. That places this record below the midpoint for gastroenterology clinicians in MA, where the typical reported total is $854.
Across 34 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironwood Pharmaceuticals, Inc$125
- AbbVie$120
- Braintree Laboratories, Inc.$115
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$104
- Boston Scientific$41
- Johnson & Johnson$37
Across 5 payments — averaging $119,481 each. An ownership or investment interest held by the physician or an immediate family member.
- Clearpoint Neuro, Inc.$597K
What the payments were for
- Food & beverage$46185%
- Education$224%
- Gifts$5811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironwood Pharmaceuticals, Inc | 1 | $125 |
| AbbVie | 6 | $120 |
| Braintree Laboratories, Inc. | 20 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $104 |
| Boston Scientific | 1 | $41 |
| Johnson & Johnson | 1 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$250
How this compares
$541 in reported general payments places this provider in the 40th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexlansoprazole DrDexlansoprazole | 11 | $4,485 |
| Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 54 | $3,716 |
| Omeprazole | 77 | $1,291 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 59 | $1,073 |
| Famotidine | 123 | $921 |
| Lansoprazole | 19 | $498 |
| Pantoprazole Sodium | 25 | $172 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Boston
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- John LeungBoston$682K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Tyler BerzinBoston$215K
- Marvin RyouBoston$162K
- Nneka UfereBoston$153K
- Christopher ThompsonBoston$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.